David Livermore - eucast

More documents

Recommendations

Info

Outcome & MIC in bacteraemias withCTX-M-3/-14 E. coli; ceftazidime 2g q8hPatient Source MIC (mg/L OutcomeM62 UTI 8 CureF49 Peritonitis 1 Responded, butdrainage neededF36 UTI 2 CureM45 Biliary infection 2 CureM67 ? 2 CureF76 HAP 8 CureF38 UTI 0.5 CureBinet al., DMID 2006; 56: 351
Look directly for ESBL Klebsiella--Where it beganUTI Ceph 2 2Non-UTICeph+aminoglycosideCeph+aminoglycosideMIC moden Cure Fail Relapse2 23 2 1RangeCefotaxime 2 0.5-4Ceftriaxone 2 0.5-4Ceftazidime 4 1-16Brun-Buisson et al Lancet 1987; ii: 302
Page 1 and 2: -Lactam susceptibility testsAcademi
Page 3: Mortality in ESBL vs. non-ESBLEnter
Page 9 and 10: Ceftazidime MICs for Enterobacteria
Page 11 and 12: E. coli NCTC13352. K-12 derivativew
Page 13 and 14: NCTC13352: Unedited results forcefo
Page 15 and 16: Third (& Say it in whispers…)For
Page 17 and 18: Delay in appropriate R x ESBL vs.no
Page 19 and 20: Chromogenic media to detectESBL pro
Page 22 and 23: Cica b-Test (Mast) blind testingof
Page 24 and 25: Carbapenem R x in infectionswith KP
Page 26 and 27: Fourth point: only by beingalert do
Page 28: Report by mechanism• Ceph MICs of

David Livermore - eucast

Create successful ePaper yourself

Delete template?

Save as template?